Corline Biomedical AB(SE:CLBIO)
kr 13.80+0.90 (+6.98%)
SE:CLBIO
Corline Biomedical AB financials statements
kr 13.80
At close:+0.90 (+6.98%)
Want to see SE:CLBIO full AI Analyst Report?
Corline Biomedical AB (CLBIO) Ratios
0 Followers
Corline Biomedical AB Ratios
SE:CLBIO's free cash flow for Q2 2026 was kr104.00K. For the 2026 fiscal year, SE:CLBIO's free cash flow was decreased by kr-19.00K and operating cash flow was kr123.00K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.98 | 2.68 | 3.51 | 5.00 | 4.75 |
| Quick Ratio | 4.98 | 2.68 | 3.51 | 5.00 | 4.85 |
| Cash Ratio | 4.27 | 2.25 | 2.51 | 3.64 | 4.42 |
| Solvency Ratio | -3.04 | -2.94 | -0.25 | 0.33 | -0.73 |
| Operating Cash Flow Ratio | -3.67 | -1.10 | 0.13 | -0.90 | -0.51 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | kr 19.16M | kr 13.20M | kr 17.01M | kr 28.80M | kr 35.39M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.05 | 1.09 | 1.07 | 1.08 | 1.10 |
| Debt Service Coverage Ratio | 0.00 | -720.84 | -64.85 | 0.00 | -528.62 |
| Interest Coverage Ratio | 0.00 | -723.94 | -68.77 | 0.00 | -531.46 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 1.46 | 0.77 | 10.09 | -10.99 | 6.05 |
| Profitability Margins | |||||
| Gross Profit Margin | -185.70% | 137.50% | 113.38% | 96.50% | 128.89% |
| EBIT Margin | -185.70% | -236.95% | -7.12% | 9.89% | -97.83% |
| EBITDA Margin | -184.60% | -235.98% | -6.74% | 10.13% | -97.39% |
| Operating Profit Margin | -185.70% | -236.99% | -7.14% | 9.89% | -97.83% |
| Pretax Profit Margin | -192.31% | -237.28% | -7.23% | 9.89% | -98.02% |
| Net Profit Margin | -192.31% | -237.28% | -7.23% | 9.89% | -97.93% |
| Continuous Operations Profit Margin | -192.31% | -237.28% | -7.23% | 9.89% | -98.02% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 99.91% |
| EBT Per EBIT | 103.56% | 100.12% | 101.17% | 100.00% | 100.19% |
| Return on Assets (ROA) | -14.93% | -24.48% | -1.81% | 2.29% | -6.80% |
| Return on Equity (ROE) | -15.69% | -26.69% | -1.94% | 2.46% | -7.50% |
| Return on Capital Employed (ROCE) | -15.15% | -26.65% | -1.92% | 2.46% | -7.49% |
| Return on Invested Capital (ROIC) | -15.15% | -26.65% | -1.92% | 2.46% | -7.48% |
| Return on Tangible Assets | -60.94% | -109.08% | -7.50% | 6.42% | -15.37% |
| Earnings Yield | -3.63% | -12.11% | -0.56% | 1.18% | -2.32% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.32 | 3.72 | 3.69 | 2.41 | 2.22 |
| Payables Turnover | 23.58 | -1.19 | -1.70 | 0.19 | -1.04 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 2.29 |
| Fixed Asset Turnover | 47.23 | 44.63 | 79.71 | 84.11 | 38.80 |
| Asset Turnover | 0.08 | 0.10 | 0.25 | 0.23 | 0.07 |
| Working Capital Turnover Ratio | 0.47 | 0.65 | 1.09 | 0.73 | 0.35 |
| Cash Conversion Cycle | 94.53 | 405.42 | 313.69 | -1771.19 | 674.13 |
| Days of Sales Outstanding | 110.01 | 98.17 | 98.94 | 151.70 | 164.57 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 159.06 |
| Days of Payables Outstanding | 15.48 | -307.25 | -214.75 | 1922.89 | -350.51 |
| Operating Cycle | 110.01 | 98.17 | 98.94 | 151.70 | 323.63 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.72 | -0.40 | 0.04 | -0.30 | -0.24 |
| Free Cash Flow Per Share | -0.72 | -0.74 | -0.45 | -0.72 | -0.71 |
| Dividend Paid and CapEx Coverage Ratio | -376.36 | -1.15 | 0.08 | -0.72 | -0.50 |
| Capital Expenditure Coverage Ratio | -376.36 | -1.15 | 0.08 | -0.72 | -0.50 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | -2.31 | -0.88 | 0.04 | -0.27 | -0.68 |
| Free Cash Flow Yield | -4.37% | -8.43% | -3.04% | -7.80% | -4.84% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -27.80 | -8.26 | -177.01 | 85.08 | -43.15 |
| Price-to-Sales (P/S) Ratio | 53.02 | 19.59 | 12.79 | 8.41 | 42.26 |
| Price-to-Book (P/B) Ratio | 4.33 | 2.20 | 3.43 | 2.09 | 3.24 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -22.87 | -11.87 | -32.89 | -12.82 | -20.65 |
| Price-to-Operating Cash Flow Ratio | -22.93 | -22.17 | 361.41 | -30.71 | -61.72 |
| Price-to-Earnings Growth (PEG) Ratio | 0.63 | -0.01 | 1.00 | -0.64 | 2.27 |
| Enterprise Value Multiple | -27.26 | -7.54 | -179.83 | 72.09 | -37.33 |
| Enterprise Value | 385.08M | 173.84M | 303.20M | 171.94M | 256.79M |
| EV to EBITDA | -27.26 | -7.54 | -179.83 | 72.09 | -37.33 |
| EV to Sales | 50.33 | 17.78 | 12.11 | 7.30 | 36.36 |
| EV to Free Cash Flow | -21.71 | -10.77 | -31.15 | -11.13 | -17.77 |
| EV to Operating Cash Flow | -21.77 | -20.12 | 342.21 | -26.65 | -53.11 |
| Tangible Book Value Per Share | 0.78 | 0.62 | 0.81 | 1.35 | 1.74 |
| Shareholders’ Equity Per Share | 3.79 | 3.98 | 4.34 | 4.40 | 4.51 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.31 | 0.45 | 1.16 | 1.10 | 0.35 |
| Net Income Per Share | -0.59 | -1.06 | -0.08 | 0.11 | -0.34 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.04 | 1.00 | 1.01 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 2.76 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.20 | 0.37 | -0.50 | -2.77 | 0.70 |
Currency in SEK
